Mohamad B Taha1,2, Tamer Yahya1,2, Priyanka Satish1, Rachel Laird1, Arthur S Agatston3, Miguel Cainzos-Achirica1,2, Kershaw V Patel1, Khurram Nasir4,5. 1. Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, 6550 Fannin St Suite 1801, Houston, TX77030, USA. 2. Center for Outcomes Research, Houston Methodist, Houston, TX, USA. 3. Department of Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA. 4. Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, 6550 Fannin St Suite 1801, Houston, TX77030, USA. knasir@houstonmethodist.org. 5. Center for Outcomes Research, Houston Methodist, Houston, TX, USA. knasir@houstonmethodist.org.
Abstract
PURPOSE OF REVIEW: The burden of obesity worldwide is high and projected to rise. Obesity increases the risk of several cardiovascular diseases and cardiometabolic risk factors; hence, utilizing effective long-term therapies for obesity is of utmost importance. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as effective therapies that achieve substantial weight loss and improve cardiometabolic risk. The purpose of this review is to discuss the role of GLP-1RAs in obesity management. RECENT FINDINGS: Two subcutaneous GLP-1RAs, liraglutide and semaglutide, have been evaluated in several clinical trials for weight loss. Liraglutide achieves a mean weight loss of 4-7 kg, and more than 50% of treated individuals achieve 5% or more weight loss. Semaglutide has a greater impact on weight loss, with a mean weight loss of 9-16 kg, and more than 50% of treated individuals achieve 10-15% or more weight loss. These results led to regulatory approval of these agents for weight loss in individuals with obesity, regardless of diabetes status. In addition to weight loss, the benefits of GLP-1RAs extend to other risk factors, such as glycemic control and blood pressure. Gastrointestinal symptoms are the most frequently encountered adverse events with incidences between 5 and 30%. Finally, the cost remains one of the most critical challenges that limit GLP-1RAs use. GLP-1RAs have robust weight loss benefits and are expected to have a critical role in the management of obesity in the coming years. Upcoming studies will evaluate the durability of weight loss achieved with GLP-1RAs and the impact on cardiovascular outcomes.
PURPOSE OF REVIEW: The burden of obesity worldwide is high and projected to rise. Obesity increases the risk of several cardiovascular diseases and cardiometabolic risk factors; hence, utilizing effective long-term therapies for obesity is of utmost importance. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as effective therapies that achieve substantial weight loss and improve cardiometabolic risk. The purpose of this review is to discuss the role of GLP-1RAs in obesity management. RECENT FINDINGS: Two subcutaneous GLP-1RAs, liraglutide and semaglutide, have been evaluated in several clinical trials for weight loss. Liraglutide achieves a mean weight loss of 4-7 kg, and more than 50% of treated individuals achieve 5% or more weight loss. Semaglutide has a greater impact on weight loss, with a mean weight loss of 9-16 kg, and more than 50% of treated individuals achieve 10-15% or more weight loss. These results led to regulatory approval of these agents for weight loss in individuals with obesity, regardless of diabetes status. In addition to weight loss, the benefits of GLP-1RAs extend to other risk factors, such as glycemic control and blood pressure. Gastrointestinal symptoms are the most frequently encountered adverse events with incidences between 5 and 30%. Finally, the cost remains one of the most critical challenges that limit GLP-1RAs use. GLP-1RAs have robust weight loss benefits and are expected to have a critical role in the management of obesity in the coming years. Upcoming studies will evaluate the durability of weight loss achieved with GLP-1RAs and the impact on cardiovascular outcomes.
Authors: Rik P Bogers; Wanda J E Bemelmans; Rudolf T Hoogenveen; Hendriek C Boshuizen; Mark Woodward; Paul Knekt; Rob M van Dam; Frank B Hu; Tommy L S Visscher; Alessandro Menotti; Roland J Thorpe; Konrad Jamrozik; Susanna Calling; Bjørn Heine Strand; Martin J Shipley Journal: Arch Intern Med Date: 2007-09-10
Authors: Richard F Hamman; Rena R Wing; Sharon L Edelstein; John M Lachin; George A Bray; Linda Delahanty; Mary Hoskin; Andrea M Kriska; Elizabeth J Mayer-Davis; Xavier Pi-Sunyer; Judith Regensteiner; Beth Venditti; Judith Wylie-Rosett Journal: Diabetes Care Date: 2006-09 Impact factor: 19.112
Authors: Michael Ej Lean; Wilma S Leslie; Alison C Barnes; Naomi Brosnahan; George Thom; Louise McCombie; Carl Peters; Sviatlana Zhyzhneuskaya; Ahmad Al-Mrabeh; Kieren G Hollingsworth; Angela M Rodrigues; Lucia Rehackova; Ashley J Adamson; Falko F Sniehotta; John C Mathers; Hazel M Ross; Yvonne McIlvenna; Renae Stefanetti; Michael Trenell; Paul Welsh; Sharon Kean; Ian Ford; Alex McConnachie; Naveed Sattar; Roy Taylor Journal: Lancet Date: 2017-12-05 Impact factor: 79.321
Authors: Renate B Schnabel; Xiaoyan Yin; Philimon Gona; Martin G Larson; Alexa S Beiser; David D McManus; Christopher Newton-Cheh; Steven A Lubitz; Jared W Magnani; Patrick T Ellinor; Sudha Seshadri; Philip A Wolf; Ramachandran S Vasan; Emelia J Benjamin; Daniel Levy Journal: Lancet Date: 2015-05-07 Impact factor: 79.321
Authors: Edward Gregg; John Jakicic; George Blackburn; Paul Bloomquist; George Bray; Jeanne Clark; Mace Coday; Jeffrey Curtis; Caitlin Egan; Mary Evans; John Foreyt; Gary Foster; Helen Hazuda; James Hill; Edward Horton; Van Hubbard; Robert Jeffery; Karen Johnson; Abbas Kitabchi; William Knowler; Andrea Kriska; Wei Lang; Cora Lewis; Maria Montez; David Nathan; Rebecca Neiberg; Jennifer Patricio; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; Bruce Redmon; Judith Regensteiner; Jack Rejeski; Paul Ribisl; Monika Safford; Kerry Stewart; Dace Trence; Thomas Wadden; Rena Wing; Susan Yanovski Journal: Lancet Diabetes Endocrinol Date: 2016-08-30 Impact factor: 32.069
Authors: Emanuele Di Angelantonio; Shilpa Bhupathiraju; David Wormser; Pei Gao; Stephen Kaptoge; Amy Berrington de Gonzalez; Benjamin Cairns; Rachel Huxley; Chandra Jackson; Grace Joshy; Sarah Lewington; JoAnn Manson; Neil Murphy; Alpa Patel; Jonathan Samet; Mark Woodward; Wei Zheng; Maigen Zhou; Narinder Bansal; Aurelio Barricarte; Brian Carter; James Cerhan; George Smith; Xianghua Fang; Oscar Franco; Jane Green; Jim Halsey; Janet Hildebrand; Keum Jung; Rosemary Korda; Dale McLerran; Steven Moore; Linda O'Keeffe; Ellie Paige; Anna Ramond; Gillian Reeves; Betsy Rolland; Carlotta Sacerdote; Naveed Sattar; Eleni Sofianopoulou; June Stevens; Michael Thun; Hirotsugu Ueshima; Ling Yang; Young Yun; Peter Willeit; Emily Banks; Valerie Beral; Zhengming Chen; Susan Gapstur; Marc Gunter; Patricia Hartge; Sun Jee; Tai-Hing Lam; Richard Peto; John Potter; Walter Willett; Simon Thompson; John Danesh; Frank Hu Journal: Lancet Date: 2016-07-13 Impact factor: 79.321